Pritelivir (AIC316) is an inhibitor of the viral helicase-primase complex, which exhibits antiviral activity in vitro and in animal models of herpes simplex virus (HSV) infection. Pritelivir is active against herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) with the IC50 of 0.02 μM against HSV1-2[1].
体内研究
Pritelivir is a pioneering agent in antiviral treatment that interrupts HSV replication by targeting the viral helicase-primase enzyme complex.
Pritelivir, at dosages ranging from 0.03 to 45 mg/kg, significantly improves survival rates and, at 0.3 to 30 mg/kg, reduces mortality against HSV-1, E-377, thereby demonstrating potent and breakthrough antiviral efficiency with the potential for managing life-threatening HSV-1 and -2 infections, including herpes simplex encephalitis.
Compared with the control treatment group, 0.1 or 0.3 mg/kg/ dose of pritlivir combined with acyclovir (10 mg/kg/ dose) had a protective effect against HSV-2 MS strains [3].
搜索
